Alfonzo J P, Rosario M N, Ugarte C, Banasco J, Fraxedas R, Lahera J
Instituto de Nefrología, 26 y Boyeros, Plaza 10600, AP 6358 La Habana, Cuba.
Nefrologia. 2003;23(2):150-9.
The aim of this study was to present our clinical experience and results of different treatments in 83 atherosclerotic renovascular hypertensive patients treated in the last 15 years in the Instituto de nefrologia in Havana. Regardless of the type of treatment the patients were divided in two groups. Group I: 52 (62.3%) cases with standard oral hypotensive drugs alone and control of other cardiovascular risk factors (mean age 53 years old, sex m/f 50/50%, race white/no-white 75/25%, mean known hypertension follow-up 10.2 +/- 10 years, mean SBP 208 +/- 30 mmHg, mean DBP 123 +/- 17 mmHg, mean serum creatinina 1.62 mg/dl and increase peripheral plasma renin value in 61.6% of patients) and group II: 31 (37.7%) cases treated with revascularización procedures (PTA or surgery) or nephrectomy in selected patients (mean age 50 years old, sex m/f 68/32%, race white/no-white 16/84%, mean known hypertension follow-up 8.5 +/- 8.6 years, mean SBP 214 +/- 32 mmHg, mean DBP 1.31 +/- 16 mmHg, mean serum creatinina 1.85 mg/dl and increase peripheral plasma renin value 78.3% of patients). As end point for treatment results we selected: 1) hypertension cure or control, 2) evolution of the serum creatinine value and 3) kidney and patients survival.
In those cases with a follow up for more than one year, in 82.9% the blood pressure was cure (21.4%) or controlled (61.4%). The proportion of failed was superior in group I (20.9%) than in group II (11.1%). All 18 cases treated by PTA with a follow up period longer than a year, blood pressure cure in 10 (55.6%), ameliorate in 5 (27.8%) and in 3 (16.6%) was unchanged (one patient lost of follow up). Nine patients were treated by surgery (3 revascularization and 6 nephrectomy), 5 (55.5%) cases cured and 4 (44.5%) ameliorate his blood pressure. Patients in group II maintain normal renal function in more cases than in group I (48.4% vs 30.8%). Both group had similar percentage of normal-normal + pathology-normal renal function (G I: 65.4% vs G II: 77.4%) p = 0.29. When chronic renal function was present at the base line study none of the revascularization procedure were superior. Patient and Kidney actuarial survivals rate do not showed superiority for any treatment procedure after 10 years of follow up.
In atherosclerosis renovascular hypertension patients treated with intervention procedure had better BP control than those treated by hypotensive drugs. Not significant different between intervention procedures and drugs treatment in renal function preservation or in patient and kidney actuarial survival rate were found in these patients.
本研究的目的是介绍我们在哈瓦那肾病研究所过去15年中治疗的83例动脉粥样硬化性肾血管性高血压患者的临床经验及不同治疗方法的结果。无论采用何种治疗方法,患者均被分为两组。第一组:52例(62.3%),仅使用标准口服降压药物并控制其他心血管危险因素(平均年龄53岁,男女比例50/50%,种族白种人/非白种人75/25%,已知高血压平均随访时间10.2±10年,平均收缩压208±30 mmHg,平均舒张压123±17 mmHg,平均血清肌酐1.62 mg/dl,61.6%的患者外周血浆肾素值升高);第二组:31例(37.7%),采用血管重建术(经皮腔内血管成形术或手术)或对部分患者进行肾切除术(平均年龄50岁,男女比例68/32%,种族白种人/非白种人16/84%,已知高血压平均随访时间8.5±8.6年,平均收缩压214±32 mmHg,平均舒张压131±16 mmHg,平均血清肌酐1.85 mg/dl,78.3%的患者外周血浆肾素值升高)。作为治疗结果的终点,我们选择:1)高血压治愈或控制;2)血清肌酐值的变化;3)肾脏及患者的生存率。
在随访超过一年的病例中,82.9%的患者血压得到治愈(21.4%)或控制(61.4%)。第一组治疗失败的比例(20.9%)高于第二组(11.1%)。所有18例接受经皮腔内血管成形术且随访时间超过一年的患者,血压治愈10例(55.6%),改善5例(27.8%),3例(16.6%)无变化(1例患者失访)。9例患者接受手术治疗(3例血管重建术和6例肾切除术),5例(55.5%)血压治愈,4例(44.5%)血压改善。第二组患者肾功能肾功能维持肾功能正常的情况比第一组更多(48.4%对30.8%)。两组肾功能正常 + 病理正常的比例相似(第一组:65.4%对第二组:77.4%),p = 0.29。在基线研究时存在慢性肾功能不全的情况下,没有一种血管重建术更具优势。随访10年后,任何治疗方法在患者和肾脏精算生存率方面均未显示出优势。
在动脉粥样硬化性肾血管性高血压患者中,采用干预治疗的患者血压控制优于使用降压药物治疗的患者。在这些患者中,干预治疗与药物治疗在肾功能保护或患者及肾脏精算生存率方面没有显著差异。